Juvelook (PDLLA 42,5mg+ HA 7,5mg) CE 5ml

The product can only be used by professionals.

Upon completion of the purchase, you will know that you are a doctor or cosmetologist trained in the design of aesthetic medicine.


Availability: 3 in stock

Juvelook (PDLLA 42,5mg+ HA 7,5mg) CE 5ml

SKU 12158-2 Categories ,

The only one in the world poly D, L lactic acid for use in the eye area, mesotherapy of the face, neck and décolleté.

It provides the effect of immediate filling and the extended action of stimulating the production of collagen, and consequently improving the volume and elasticity of the skin.

Juvelook is a combination of hyaluronic acid and poly DL lactic acid.

Since the molecule contains 2 substances, we are talking about a hybrid filler.

Juvelook is the only PDLLA preparation in the world intended for the treatment of the delicate area of ​​the lower eyelid and tear valley, thin skin of the neck and for mesotherapy of the facial skin. This is possible because the molecule of the preparation has a size of 10 to 40 microns.

Its heart is a tissue stimulator PDLLA acid surrounded by non-cross-linked hyaluronic acid. This is why the hydration of the skin is visible immediately after the treatment, which significantly improves the working conditions of fibroblasts stimulated by PDLLA.


Safety supported by clinical trials, which led to the obtaining of two patents first, then the CE certificate necessary to introduce the substance to the European market.

Stimulation has been proven to produce a controlled inflammation.

Photographs of histopathological sections show the orderly distribution of molecules in the skin, surrounded by freshly produced collagen fibers.


Dark circles under the eyes
Volume loss in the area of ​​the lower eyelid
The marked valley of tears
Flabbiness of the skin of the neck, skin of the hands, skin of the face
Illumination and firming of the skin
Rejuvenation of the eye area
Smoothing wrinkles
Permanent tension and nourishment of the skin

Mechanism of action

Immediately after injection, the preparation fills the tissues with non-cross-linked hyaluronic acid. Polylactic acid microparticles provide cohesiveness to the hyaluronic acid hydrogel, preventing its displacement, and thus the filling effect is immediate and noticeable.
After 2 weeks, when hyaluronic acid begins to hydrolyze, PLA microparticles are activated, stimulating the production of collagen and, consequently, gradually and long-lastingly improving the elasticity, firmness and density of the skin.
After 6 months, we can see the full effect of the treatments. Until then, the preparation has been gradually biodegradable, restoring the skin’s volume and elasticity.


The only formula of the hybrid Poly D, L Lactyd + HA in the world with a particle size from 10 to 40 micrometers
Efficacy and safety confirmed by clinical trials
Durability of effects – over 2 years from the last treatment
Immediate effect – due to hyaluronic acid
Safety – FDA and CE certificates for polylactic acid
Patents and own clinical trials
Particle size from 10 to 40 microns
Comfort of the procedure – easy injection and no needle clogging during the procedure


Polylactic acid (PDLLA – Poly D, L Lactyd) 42.5 mg (particle size 10-40 micrometers)
Uncross-linked hyaluronic acid 7.5 mg (particle size 3000 kDa)


The effects of the therapy are visible immediately after administration.
After two weeks, collagen production begins, activated by the presence of PDLLA lactic acid microparticles.
The effects of the therapy last for over two years after the last treatment.
The recommended number of treatments is 2 or 3, depending on the type of problem, at intervals of 6-8 weeks. After two years, we recommend performing 1 reminder treatment.


Patent: No. 10-1481441 Manufacturing method of polymeric microparticles having network structure – Method for producing polymeric microparticles with network structure
Patent: No. 10-1725279 A process for the preparation of polylactic acid microparticles by a spray method – The process of obtaining polylactic acid microparticles by the spray method – spherical, porous shape


Active infection
Diseases from the group of collagen diseases
Active, unregulated autoimmune diseases
Allergy to the ingredients of the preparation
Skin inflammation in the area of ​​the planned treatment






There are no reviews yet

Be the first to review “Juvelook (PDLLA 42,5mg+ HA 7,5mg) CE 5ml”
Shopping Cart
    Your Cart
    Your cart is emptyReturn to Shop